Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $7.67 million versus the consensus estimate of $12.15 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.